| pubmed-article:7836705 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C0080225 | lld:lifeskim |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C0282440 | lld:lifeskim |
| pubmed-article:7836705 | lifeskim:mentions | umls-concept:C1096777 | lld:lifeskim |
| pubmed-article:7836705 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7836705 | pubmed:dateCreated | 1995-2-27 | lld:pubmed |
| pubmed-article:7836705 | pubmed:abstractText | Strategies of treatment of chronic hepatitis type B are currently based on the use of either antiviral or immunomodulatory agents. A randomized, controlled trial was performed to assess the safety and efficacy of 6-month thymopentin therapy in 30 patients with chronic hepatitis B. Inclusion criteria were biopsy-proven chronic hepatitis, elevated alanine aminotransferase and serum HBsAg and HBV-DNA positivity for at least 12 months. At the conclusion of the study (1 year), HBV-DNA was negative and alanine aminotransferase had normalized in 13% and 20% of treated cases and in 20% and 27% of controls. None of the ten treated and one of the nine control patients who were initially HBeAg positive subsequently cleared HBeAg. None became HBsAg negative. A histologic improvement was noted in 27% of the treated patients compared with 18% of controls. These results indicate that this regimen of thymopentin therapy is not effective in treating chronic hepatitis B. | lld:pubmed |
| pubmed-article:7836705 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7836705 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7836705 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7836705 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7836705 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7836705 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7836705 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7836705 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7836705 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7836705 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:AlbertiAA | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:RuolAA | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:GiustinaGG | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:FattovichGG | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:PontissoPP | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:GuidoMM | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:BenvegnùLL | lld:pubmed |
| pubmed-article:7836705 | pubmed:author | pubmed-author:FavaratoSS | lld:pubmed |
| pubmed-article:7836705 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7836705 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:7836705 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7836705 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7836705 | pubmed:pagination | 361-6 | lld:pubmed |
| pubmed-article:7836705 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:meshHeading | pubmed-meshheading:7836705-... | lld:pubmed |
| pubmed-article:7836705 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7836705 | pubmed:articleTitle | A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. | lld:pubmed |
| pubmed-article:7836705 | pubmed:affiliation | Istituto di Semeiotica e Nefrologia Medica, University of Verona, Italy. | lld:pubmed |
| pubmed-article:7836705 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7836705 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7836705 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7836705 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7836705 | lld:pubmed |
